Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors

Summary

multi-centre, prospective, diagnostic trial to evaluate the Prostate-Specific Membrane Antigen (PSMA-antigen) over-expression in metastatic castration resistant prostate cancer (mCRPC) and in advanced/metastatic solid tumors patients.

Timeline

Start

2017-07-04

Primary completion

2024-12-04

Completion

2025-01-03

Drugs

Indications